Vera Therapeutics, Inc. Payments to Acquire Marketable Securities
Vera Therapeutics, Inc. (VERA) reported Payments to Acquire Marketable Securities of $308.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- Vera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $98.06M, a 0.82% increase year-over-year.
- Vera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $210.56M, a 133.98% increase year-over-year.
- Vera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $24.50M, a 91.67% decline year-over-year.
- Vera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $98.70M, a 35.30% increase year-over-year.
- Vera Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $310.45M, a 55.84% decline from fiscal 2024.
- Vera Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $703.01M, a 212.55% increase from fiscal 2023.
- Vera Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $224.93M, a 51.48% increase from fiscal 2022.
- Vera Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $148.49M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $98.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $308.62M 10-Q · filed 2026-08-10 | $333.12M derived: sum of 3 quarters · filed 2026-08-10 | $431.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $210.56M 10-Q · filed 2026-05-07 | $235.06M derived: sum of 2 quarters · filed 2026-05-07 | $333.76M derived: sum of 3 quarters · filed 2026-05-07 | $431.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $24.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $123.19M derived: sum of 2 quarters · filed 2026-02-26 | $220.45M derived: sum of 3 quarters · filed 2026-08-10 | $310.45M 10-K · filed 2026-02-26 |
| 2025-09-30 | $98.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $195.96M derived: sum of 2 quarters · filed 2026-08-10 | $285.95M 10-Q · filed 2025-11-05 | $579.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $97.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $187.25M 10-Q · filed 2026-08-10 | $481.27M derived: sum of 3 quarters · filed 2026-08-10 | $554.21M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $89.99M 10-Q · filed 2026-05-07 | $384.01M derived: sum of 2 quarters · filed 2026-05-07 | $456.95M derived: sum of 3 quarters · filed 2026-05-07 | $538.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $294.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $366.96M derived: sum of 2 quarters · filed 2026-02-26 | $448.05M derived: sum of 3 quarters · filed 2026-02-26 | $703.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | $72.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $154.03M derived: sum of 2 quarters · filed 2025-11-05 | $409.00M 10-Q · filed 2025-11-05 | $462.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $81.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $336.06M 10-Q · filed 2025-08-05 | $389.25M derived: sum of 3 quarters · filed 2026-02-26 | $417.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $254.97M 10-Q · filed 2025-05-07 | $308.17M derived: sum of 2 quarters · filed 2026-02-26 | $336.84M derived: sum of 3 quarters · filed 2026-02-26 | $445.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $53.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $81.87M derived: sum of 2 quarters · filed 2026-02-26 | $190.72M derived: sum of 3 quarters · filed 2026-02-26 | $224.93M 10-K · filed 2026-02-26 |
| 2023-09-30 | $28.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $137.52M derived: sum of 2 quarters · filed 2024-11-07 | $171.73M 10-Q · filed 2024-11-07 | $182.29M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $108.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $143.06M 10-Q · filed 2024-08-08 | $153.62M derived: sum of 3 quarters · filed 2024-08-08 | $194.02M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $34.21M 10-Q · filed 2024-05-10 | $44.77M derived: sum of 2 quarters · filed 2024-05-10 | $85.17M derived: sum of 3 quarters · filed 2024-05-10 | $143.26M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $10.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $50.97M derived: sum of 2 quarters · filed 2024-03-27 | $109.05M derived: sum of 3 quarters · filed 2024-03-27 | $148.49M 10-K · filed 2024-03-27 |
| 2022-09-30 | $40.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $98.49M derived: sum of 2 quarters · filed 2023-11-09 | $137.93M 10-Q · filed 2023-11-09 | $137.93M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $58.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $97.52M 10-Q · filed 2023-08-10 | $97.52M derived: sum of 3 quarters · filed 2023-08-10 | $97.52M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $39.44M 10-Q · filed 2023-05-11 | $39.44M derived: sum of 2 quarters · filed 2023-05-11 | $39.44M derived: sum of 3 quarters · filed 2023-05-11 | $39.44M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |